Adjuvant Atezo in Stage II/IIIA Lung Cancer: A New Standard? Adjuvant Atezo in Stage II/IIIA Lung Cancer: A New Standard?

Dr Mark Kris discusses a recent trial demonstrating improved disease-free survival for patients with resected stage II to IIIA, PD-L1-positive lung cancer treated with atezolizumab following cisplatin-based chemotherapy.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news